Germany · Delayed Price · Currency is EUR Xenon Pharmaceuticals Company Description
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.
Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Country | Canada |
| Founded | 1996 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 327 |
| CEO | Ian Mortimer |
Contact Details
Address: 200-3650 Gilmore Way Burnaby, British Columbia V5G 4W8 Canada | |
| Phone | 604 484 3300 |
| Website | xenon-pharma.com |
Stock Details
| Ticker Symbol | XP0 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ian Mortimer | Chief Executive Officer |
| Thomas Kelly | Chief Financial Officer |
| Matthew Ronsheim | Chief Operating Officer |